12. Hematopoietic Stem-Cell Transplantation for Acute Myelogenous Leukemia

  1. Stefan Faderl MD Associate Professor and
  2. Hagop Kantarjian MD Chairman Professor
  1. Gheath Alatrash DO, PhD Assistant Professor of Medicine1 and
  2. Marcos de Lima MD Associate Professor of Medicine2

Published Online: 4 JAN 2011

DOI: 10.1002/9781444327359.ch12

Leukemias: Principles and Practice of Therapy

Leukemias: Principles and Practice of Therapy

How to Cite

Alatrash, G. and de Lima, M. (2010) Hematopoietic Stem-Cell Transplantation for Acute Myelogenous Leukemia, in Leukemias: Principles and Practice of Therapy (eds S. Faderl and H. Kantarjian), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444327359.ch12

Editor Information

  1. Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA

Author Information

  1. 1

    Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA

  2. 2

    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA

Publication History

  1. Published Online: 4 JAN 2011
  2. Published Print: 26 NOV 2010

ISBN Information

Print ISBN: 9781405182355

Online ISBN: 9781444327359

SEARCH

Keywords:

  • stem cell transplant;
  • preparative regimen;
  • graft-versus-host disease;
  • graft-versus-leukemia;
  • allogeneic;
  • autologous;
  • haploidentical;
  • umbilical cord transplant

Summary

Hematopoietic stem cell transplantation (HSCT) is a key therapeutic modality for the management of acute myeloid leukemia (AML). Advances in preparative regimens and post-transplant supportive care have extended the use of HSCT to populations that were excluded in the past, such as the elderly and those with comorbidities. However, with increasing eligibility come the difficulties of integrating transplantation with new medications with efficacy in AML. Herein, we discuss HSCT, including the types of transplants offered for patients with AML, preparative regimens, timing of transplant, and factors involved in patient selection. We also speculate on future advances and directions that may alter the way HSCT is currently performed to treat AML.